What's Happening

Stay up to date on pharmaceutical developments, industry issues, and what’s happening with Healthesystems

Events

Healthesystems’ conferences and speaking engagements

WCI Annual Conference

August 21-24, 2022 in Orlando Florida

Visit Healthe in booth #913 to learn more about our workers’ comp pharmacy & ancillary benefits

National Comp (NWCD Conference)

October 19-21, 2022 Las Vegas, Nevada

Visit Healthe in booth #621 to participate in our Annual Industry Survey for a chance to win $500

Attend our VP of Clinical Services, Dr. Silvia Sacalis’ session on Thursday 10/20 @ 2pm: “Building an Employee Culture of Well-Being and Trust Amid COVID and Beyond”

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Igalmi (dexmedetomidine) sublingual film

Approval Date: Apr 2022

Note: New Product

Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder

hello world!

Vimpat (lacosamide) tablets

Approval Date: Mar 2022

Note: First-Time Generic

A first-time generic for Vimpat, this drug treats partial onset seizures

hello world!

Adlarity (donepezil hydrochloride) transdermal system

Approval Date: Mar 2022

Note: New Product

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

hello world!

Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol

Approval Date: Mar 2022

Note: First-Time Generic

A first-time generic for Symbicort, this drug is indicated for the treatment of COPD and asthma.

hello world!

Farxiga (dapgliflozin) tablets

Approval Date: Feb 2022

Note: First-Time Generic

A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.

hello world!

Revex (nalmefene) injection

Approval Date: Feb 2022

Note: First-Time Generic

A first-time generic of Revex, this drug is indicated for the complete or partial reversal of opioid drug effects, including respiratory depressions from natural or synthetic opioids, and for the management of opioid overdose

hello world!

Aspruzyo Sprinkle (ranolazine) extended release granules

Approval Date: Feb 2022

Note: New Product

Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.

hello world!

Norliqva® (amlodipine) oral solution

Approval Date: Feb 2022

Note: New Product

A peppermint-flavored solution indicated for the treatment of hypertension and angina. Amlodipine is available as a generic in oral tablets.

hello world!

Fleqsuvy (baclofen) oral suspension

Approval Date: Feb 2022

Note: New Product

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

hello world!

Sovaldi (sofosbuvir) tablets

Approval Date: Jan 2022

Note: First-Time Generic

Indicated for the treatment of Hepatitis C genotypes 1-4 in patients without cirrhosis, or with compensated cirrhosis as part of a combination antiviral treatment regimen.

hello world!

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmenucross-circle